Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 485 Triple Negative Breast Neoplasms 28 Carcinoma, Non-Small-Cell Lung 22 Breast Neoplasms, Male 22 Neoplasms 20 Inflammatory Breast Neoplasms 20 Neoplasm Metastasis 19 Prostatic Neoplasms 17 HER2-positive Breast Cancer 16 Ovarian Neoplasms 13 Lung Neoplasms 13 Stomach Neoplasms 12 Squamous Cell Carcinoma of Head and Neck 10 Head and Neck Neoplasms 9 Melanoma 8 Esthesioneuroblastoma, Olfactory 8 Carcinoma, Renal Cell 8 Urinary Bladder Neoplasms 7 Small Cell Lung Carcinoma 7 Salivary Gland Neoplasms 7 Pancreatic Neoplasms 7 Esophageal Neoplasms 7 Neutropenia 6 Breast Diseases 6 Sarcoma 5 Carcinoma, Ovarian Epithelial 5 Uterine Cervical Neoplasms 4 Primary Breast Cancer 4 Pathologic Complete Response 4 Endometrial Neoplasms 4

Interventions

pertuzumab 1 azeliragon 1 Trastuzumab 1 Docetaxel 1 Cyclophosphamide 1 Carboplatin 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Cancer Related Cognitive Decline × Docetaxel × Breast × Clear all

NCT05256745 2025-12-24

RAGE

Georgetown University

Phase 1/2 Recruiting

Cancer Related Cognitive Decline

Data powered by HemOnc (CC BY 4.0) Colophon ⚡